Ocular Therapeutix, Inc. (OCUL)
NASDAQ: OCUL · Real-Time Price · USD
9.16
-0.34 (-3.58%)
At close: May 15, 2026, 4:00 PM EDT
9.25
+0.09 (0.98%)
After-hours: May 15, 2026, 6:49 PM EDT
Ocular Therapeutix Employees
Ocular Therapeutix had 325 employees as of December 31, 2025. The number of employees increased by 51 or 18.61% compared to the previous year.
Employees
325
Change (1Y)
51
Growth (1Y)
18.61%
Revenue / Employee
$160,117
Profits / Employee
-$893,840
Market Cap
2.01B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 325 | 51 | 18.61% |
| Dec 31, 2024 | 274 | 7 | 2.62% |
| Dec 31, 2023 | 267 | -7 | -2.55% |
| Dec 31, 2022 | 274 | 46 | 20.18% |
| Dec 31, 2021 | 228 | 47 | 25.97% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Sarepta Therapeutics | 835 |
| ADMA Biologics | 647 |
| Ascentage Pharma Group International | 605 |
| Intellia Therapeutics | 377 |
| Stoke Therapeutics | 170 |
| Pharvaris | 129 |
| Aurinia Pharmaceuticals | 128 |
| AnaptysBio | 104 |
OCUL News
- 1 day ago - Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 3 days ago - Ocular Therapeutix Transcript: Bank of America Global Healthcare Conference 2026 - Transcripts
- 11 days ago - Ocular Therapeutix Earnings Call Transcript: Q1 2026 - Transcripts
- 11 days ago - Ocular Therapeutix reports Q1 EPS (40c), consensus (31c) - TheFly
- 11 days ago - Ocular Therapeutix™ Reports First Quarter 2026 Financial Results and Business Highlights - GlobeNewsWire
- 17 days ago - Ocular Therapeutix enrolls first patient in Axpali trial - TheFly
- 17 days ago - Ocular Therapeutix™ Announces First Patient Enrolled in SOL-X Long-Term Extension Trial for AXPAXLI™ in Wet AMD - GlobeNewsWire
- 18 days ago - Ocular Therapeutix™ to Report First Quarter 2026 Financial Results on May 5, 2026 - GlobeNewsWire